FDA Calls for Withdrawal of Multiple Myeloma Drug Pepaxto FDA Calls for Withdrawal of Multiple Myeloma Drug Pepaxto

The drug was granted an accelerated approval, but a confirmatory phase 3 trial raised concerns about safety after showing higher mortality than in the comparator arm.News Alerts
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news